In perspective: CSL112 (apolipoprotein A-I) infusions and cardiovascular outcomes in patients with acute myocardial infarction: the ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II) trial.
Frederik Hendrik VerbruggeKonstantin A KrychtiukPublished in: European heart journal. Acute cardiovascular care (2024)